

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)



(10) International Publication Number
WO 2025/049931 A1

(51) International Patent Classification:

A61K 31/496 (2006.01) A61P 35/00 (2006.01)
A61K 31/5025 (2006.01) A61K 45/06 (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:

PCT/US2024/044705

(22) International Filing Date:

30 August 2024 (30.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/535,881 31 August 2023 (31.08.2023) US

(71) Applicant: TERNs PHARMACEUTICALS, INC.

[US/US]; 1065 E. Hillsdale Blvd., Suite 100, Foster City,
California 94404 (US).

(72) Inventors: PARSONS, Benjamin, M.; c/o Terns Pharma-

ceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster

City, California 94404 (US). JONES, Christopher, T.; c/o
Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite
100, Foster City, California 94404 (US). JASPER, Jeffrey,
R.; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd.,
Suite 100, Foster City, California 94404 (US).

(74) Agent: MANSON, Daniel, E. et al.; Cooley LLP, 1299
Pennsylvania Avenue NW, Suite 700, Washington, District
of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMBINATIONS COMPRISING BCR:ABL-1 INHIBITOR AND A SECOND TYROSINE KINASE INHIBITOR FOR
USE IN THE TREATMENT OF CANCER




FIG. 1

(57) Abstract: Provided herein are combinations for inhibiting tyrosine kinase activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*